<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药智网 | wechat-feeds</title><link>http://MzAxODA5MTU3NQ.favicon.privacyhide.com/favicon.ico</link><description>让药物创造变得容易！我们致力于成为中国健康产业的传播者、服务者、推动者。</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 18 Apr 2021 10:13:29 +0800</pubDate><image><url>http://MzAxODA5MTU3NQ.favicon.privacyhide.com/favicon.ico</url><title>药智网 | wechat-feeds</title><link>http://MzAxODA5MTU3NQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>【药咖君】中药1类新药「阿可拉定」申报上市！齐鲁制药又两个重磅品种过评，多款进口药新进展，辉瑞、渤健…</title><link>https://mp.weixin.qq.com/s/x68uBWMfvuVzLX5if-fCGw</link><description></description><content:encoded><![CDATA[【药咖君】中药1类新药「阿可拉定」申报上市！齐鲁制药又两个重磅品种过评，多款进口药新进展，辉瑞、渤健…]]></content:encoded><pubDate>Sat, 17 Apr 2021 23:07:09 +0800</pubDate></item><item><title>FDA近5年批准新药标准，代表了药物研发的哪些趋势？</title><link>https://mp.weixin.qq.com/s/gMjqORoXi3m1pqpkU2qqmA</link><description></description><content:encoded><![CDATA[FDA近5年批准新药标准，代表了药物研发的哪些趋势？]]></content:encoded><pubDate>Fri, 16 Apr 2021 17:49:04 +0800</pubDate></item><item><title>致渐行渐远的医药分家—漫谈药品降价史</title><link>https://mp.weixin.qq.com/s/RfxBlaApmckh4DpnjmLzXQ</link><description></description><content:encoded><![CDATA[致渐行渐远的医药分家—漫谈药品降价史]]></content:encoded><pubDate>Fri, 16 Apr 2021 17:23:21 +0800</pubDate></item><item><title>第五批集采竞争格局分析：纳入品规涨幅130%，6000亿注射剂市场巨震！</title><link>https://mp.weixin.qq.com/s/mFBFxvVn2TH1D3QBQCXWDQ</link><description></description><content:encoded><![CDATA[第五批集采竞争格局分析：纳入品规涨幅130%，6000亿注射剂市场巨震！]]></content:encoded><pubDate>Fri, 16 Apr 2021 17:23:21 +0800</pubDate></item><item><title>国际版｜医药行业“A司”到“Z司”，这些“名片”您认识多少？</title><link>https://mp.weixin.qq.com/s/l2FFSTtGI8jZD6GBHNwnkw</link><description></description><content:encoded><![CDATA[国际版｜医药行业“A司”到“Z司”，这些“名片”您认识多少？]]></content:encoded><pubDate>Fri, 16 Apr 2021 17:23:21 +0800</pubDate></item><item><title>《医药代表备案制》后时代，中国医药代表的未来7大方向？</title><link>https://mp.weixin.qq.com/s/e2u5AC1LWlM0tTJ7eqLyEw</link><description></description><content:encoded><![CDATA[《医药代表备案制》后时代，中国医药代表的未来7大方向？]]></content:encoded><pubDate>Fri, 16 Apr 2021 17:23:21 +0800</pubDate></item><item><title>200亿市场厮杀！全球仅3款获批，钾离子竞争性酸阻滞剂，风口or风险？</title><link>https://mp.weixin.qq.com/s/Su9dfvnuVp22z4II_LxP0A</link><description></description><content:encoded><![CDATA[200亿市场厮杀！全球仅3款获批，钾离子竞争性酸阻滞剂，风口or风险？]]></content:encoded><pubDate>Thu, 15 Apr 2021 14:27:14 +0800</pubDate></item><item><title>100亿EGFR抑制剂市场，阿斯利康奥西替尼新适应症获批；豪森、艾力斯....</title><link>https://mp.weixin.qq.com/s/ojR8up9KEGovhUAqkPsY6Q</link><description></description><content:encoded><![CDATA[100亿EGFR抑制剂市场，阿斯利康奥西替尼新适应症获批；豪森、艾力斯....]]></content:encoded><pubDate>Thu, 15 Apr 2021 14:27:14 +0800</pubDate></item><item><title>有奖答题猜猜猜，4月药智有您更精彩！领千元礼包 so easy！</title><link>https://mp.weixin.qq.com/s/Dlo4nTpIMaOpcDPn3HvvYQ</link><description></description><content:encoded><![CDATA[有奖答题猜猜猜，4月药智有您更精彩！领千元礼包 so easy！]]></content:encoded><pubDate>Thu, 15 Apr 2021 14:27:14 +0800</pubDate></item><item><title>重磅！第五批集采来袭，207个品规药品名单公布</title><link>https://mp.weixin.qq.com/s/lFgoaAlGkjOQnybM8xQd4w</link><description></description><content:encoded><![CDATA[重磅！第五批集采来袭，207个品规药品名单公布]]></content:encoded><pubDate>Thu, 15 Apr 2021 14:27:14 +0800</pubDate></item><item><title>涉嫌垄断！扬子江被罚7.64亿！</title><link>https://mp.weixin.qq.com/s/DyFQBWX4i-rAJLY-s5jX0g</link><description></description><content:encoded><![CDATA[涉嫌垄断！扬子江被罚7.64亿！]]></content:encoded><pubDate>Thu, 15 Apr 2021 14:27:14 +0800</pubDate></item><item><title>新药研发“卡脖子难题”有解吗？</title><link>https://mp.weixin.qq.com/s/A4vqHV9QhHmTNwyiNzIPgw</link><description></description><content:encoded><![CDATA[新药研发“卡脖子难题”有解吗？]]></content:encoded><pubDate>Wed, 14 Apr 2021 18:18:27 +0800</pubDate></item><item><title>“限抗令”升级，仿制药市场重整，阿莫西林的未来还被看好吗？</title><link>https://mp.weixin.qq.com/s/JQrnNXZKqzg6i9j6bEvUjg</link><description></description><content:encoded><![CDATA[“限抗令”升级，仿制药市场重整，阿莫西林的未来还被看好吗？]]></content:encoded><pubDate>Wed, 14 Apr 2021 18:18:27 +0800</pubDate></item><item><title>4大关键词，破解集采的密码</title><link>https://mp.weixin.qq.com/s/6PWpDW6kOWOunkbnpkVoAQ</link><description></description><content:encoded><![CDATA[4大关键词，破解集采的密码]]></content:encoded><pubDate>Wed, 14 Apr 2021 18:18:27 +0800</pubDate></item><item><title>10个大品种，带量采购开始</title><link>https://mp.weixin.qq.com/s/efZtJz7fuzIaW263j5ckzw</link><description></description><content:encoded><![CDATA[10个大品种，带量采购开始]]></content:encoded><pubDate>Wed, 14 Apr 2021 18:18:27 +0800</pubDate></item><item><title>顶格处罚19家药企的背后，是带量采购的呼啸而至</title><link>https://mp.weixin.qq.com/s/DXy0rskwJXVXZeovmQ0u-Q</link><description></description><content:encoded><![CDATA[顶格处罚19家药企的背后，是带量采购的呼啸而至]]></content:encoded><pubDate>Tue, 13 Apr 2021 17:26:51 +0800</pubDate></item><item><title>中国上亿ED患者，阿伐那非还有多少竞争空间？</title><link>https://mp.weixin.qq.com/s/8haAsfAo9y9ke4edyK0FqA</link><description></description><content:encoded><![CDATA[中国上亿ED患者，阿伐那非还有多少竞争空间？]]></content:encoded><pubDate>Tue, 13 Apr 2021 17:26:51 +0800</pubDate></item><item><title>基药986最新消息：逐步提高比率，年增长不低于4%</title><link>https://mp.weixin.qq.com/s/HOHDxVH7kI-g1Em0dgZ3hQ</link><description></description><content:encoded><![CDATA[基药986最新消息：逐步提高比率，年增长不低于4%]]></content:encoded><pubDate>Tue, 13 Apr 2021 17:26:51 +0800</pubDate></item><item><title>知名药企，总经理辞职</title><link>https://mp.weixin.qq.com/s/3g36l-D5FYqgBLcKkUiM7Q</link><description></description><content:encoded><![CDATA[知名药企，总经理辞职]]></content:encoded><pubDate>Tue, 13 Apr 2021 17:26:51 +0800</pubDate></item><item><title>医药行业“卖水人”CDMO崛起，1000亿市场，药明生物、凯莱英、康龙化成、博腾...</title><link>https://mp.weixin.qq.com/s/nLHKGcDTthuJyrzn5RtPVQ</link><description></description><content:encoded><![CDATA[医药行业“卖水人”CDMO崛起，1000亿市场，药明生物、凯莱英、康龙化成、博腾...]]></content:encoded><pubDate>Mon, 12 Apr 2021 17:57:46 +0800</pubDate></item></channel></rss>